Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-1275 mimic is a synthetic double-stranded RNA molecule designed to replicate the biological activity of endogenous microRNA-1275 (miR-1275). In the context of oncology, particularly hepatocellular carcinoma (HCC), miR-1275 acts as a tumor suppressor that is frequently downregulated. The mimic functions by binding to the 3' untranslated region (UTR) of target messenger RNAs, most notably Eukaryotic translation initiation factor 5A-2 (EIF5A2), leading to translational repression or mRNA degradation. By silencing EIF5A2, the mimic inhibits the downstream PI3K/Akt signaling pathway, which effectively restricts the epithelial-mesenchymal transition (EMT), cell stemness, proliferation, migration, and metastasis of cancer cells. Research has also indicated that its antitumor effects can be synergistically enhanced when used in combination with genistein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-1275 mimic.